Search bioRxiv⌕ Search

Biology subjects

Cirillo, D.

Publications and source records attributed to Cirillo, D..

9 recordsLinked to original sources

Interpretable Forecasting of Kidney Cancer Progression via Generative AI and Symbolic Reasoning

Predicting cancer stage progression from omics data, and deriving molecular insight into the mechanisms driving it, remains a major challenge, owing in part to the lack of adequate longitudinal data and the interpretability limitations of current forecasting models. Large cancer datasets such as TCGA capture patient profiles cross-sectionally rather than longitudinally, complicating timely treatment decisions as tumors become more invasive. Deep neural networks typically used for forecasting, such as LSTMs, compound this problem by remaining largely opaque and offering clinicians no straightforward way to audit their predictions. Clear cell renal cell carcinoma (ccRCC) illustrates the clinical stakes of both challenges. Five-year survival falls from over 94% at stage I to 28% at stage IV, yet early-stage tumors are often managed under active surveillance, a strategy constrained by sparse molecular evidence of progression risk. Detecting progression in time, meanwhile, demands forecasts clinicians can interpret and trust, not black-box predictions. We address both challenges by combining generative and symbolic AI: a Variational Autoencoder trained on bulk RNA-Seq profiles of 530 TCGA ccRCC patients generates synthetic pseudo-time trajectories that overcome the absence of longitudinal data, while a symbolic rule-induction framework (ASAL) learns finite-state automata from these trajectories, encoding stage transition as human-readable Boolean conditions over gene expression, which a complex event forecasting system (Wayeb) converts into probabilistic forecasts of stage advancement. An independent XGBoost classifier trained on real patients (F1 score = 0.71-0.81) shows a gradual early-to-late probability shift along the synthetic trajectories, absent in non-progressing control trajectories. Pathway enrichment of those trajectories reveals stage-dependent changes in established kidney cancer-related processes, including the TCA cycle and DNA repair. Finally, our symbolic forecaster nearly matches an LSTM baseline (macro F1 = 0.928 vs. 0.964), while additionally offering an inspectable rule set and a probability distribution over transition timing rather than a single opaque score. This work shows that generative and symbolic AI, paired together, can turn cross-sectional cohorts into a transparent, forecast-oriented framework for modeling disease progression, demonstrated here in ccRCC.

bioinformatics↗

A conserved transcriptional backbone and rewiring of gene-regulatory networks in activated human CD4⁺ T cells

CD4+ T cells are components of the adaptive immune system with a plethora of subtype-specific functions. In order to further dissect the activation and differentiation regulatory program(s) of individual CD4+ T cell subsets, we performed an in vitro activation and differentiation of human primary naive CD4+ T cells towards Th1, Th2, Th17 and Treg subtypes followed by the single-cell RNA-seq and ATAC-seq (multiome) analysis. Resulting multiome data were used for constructing the subtype-specific gene regulatory networks, which were next assessed for their differences/similarities among the subtypes. Surprisingly, a conserved set of 8 "backbone" transcription factors (TFs) was identified as highly central in all subtypes, however, with unique differentiation-driven rewiring tendency. Subtype-specific "driver" TFs were identified in the case of Th1-Th1_17-Th17 lineage (EOMES, HLF), naive Tregs (ESR1, DACH1), and memory Tregs (SOX13). Finally, we applied community detection algorithms to identify potential non-obvious groups of genes that regulate diverse molecular functions within the differentiated subtypes, linked to the backbone TFs. Our atlas aims at providing a high resolution understanding of the gene regulatory networks and their rewiring in human primary CD4+ T cells, upon activation and differentiation.

immunology↗

10 Years of Variational Autoencoder: Insights from Cancer Temporal Progression Studies, a Systematic Literature Review

Deep learning methods, including deep representation learning (DRL) approaches such as variational au-toencoders (VAEs), have been widely applied to cancer omics data to address the high dimensionality of these datasets. Despite remarkable advances, cancer remains a complex and dynamic disease that is challenging to study, and the temporal resolution of cancer progression captured by omics-based studies remains limited. In this systematic literature review, we explore the use of DRL, particularly the VAE, in cancer omics studies for modeling time-related processes, such as tumor progression and evolutionary dynamics. Our work reveals that these methods most commonly support subtyping, diagnosis, and prognosis in this context, but rarely emphasize temporal information. We observed that the scarcity of longitudinal omics data currently limits deeper temporal analyses that could enhance these applications. We propose that applying the VAE as a generative model to study cancer in time, for example, focusing on cancer staging, could lead to meaningful advancements in our understanding of the disease. Biographical NoteO_LIGuillermo Prol-Castelo is a PhD student at the Barcelona Supercomputing Center and Universitat Pompeu Fabra, where he works on the application of deep learning methods to cancer studies. C_LIO_LIDavide Cirillo is the head of the Machine Learning for Biomedical Research Unit at the Barcelona Supercomputing Center. He is an expert in predictive modeling for Precision Medicine using Network Biology and Machine Learning. C_LIO_LIAlfonso Valencia is the principal investigator of the Computational Biology Group at the Barcelona Supercomputing Center. He is a leading expert in protein coevolution, disease networks and modelling cellular systems. C_LIO_LIThe Barcelona Supercomputing Center is a public research center that provides high-performance computing infrastructure to support scientific research in a wide range of fields, including life sciences. C_LI Key PointsO_LIThere is a growing interest on the application of deep learning methods, such as Deep Representation Learning (DRL), to cancer studies. C_LIO_LICancer is a complex and dynamic disease, whose temporal dynamics are not yet fully captured in omics-based studies. C_LIO_LImong DRL methods, the Variational Autoencoder (VAE) using omics-based data has been widely used in cancer studies, particularly for subtyping, diagnosis, and prognosis. C_LIO_LIThe temporal aspects of cancer progression are often insufficiently captured in omics-based studies, primarily due to the scarcity of longitudinal data. C_LIO_LIApplying the VAE as a generative model to study cancer in time, such as focusing on cancer staging, could lead to significant advancements in our understanding of cancer. C_LI

bioinformatics↗

Sex-specific transcriptome similarity networks elucidate comorbidity relationships

Humans present sex-driven biological differences. Consequently, the prevalence of analyzing specific diseases and comorbidities differs between the sexes, directly impacting patients management and treatment. Despite its relevance and the growing evidence of said differences across numerous diseases (with 4,370 PubMed results published within the past year), knowledge at the comorbidity level remains limited. In fact, to date, no study has attempted to identify the biological processes altered differently in women and men, promoting differences in comorbidities. To shed light on this problem, we analyze expression data for more than 100 diseases from public repositories, analyzing each sex independently. We calculate similarities between differential expression profiles by disease pairs and find that 13-16% of transcriptomically similar disease pairs are sex-specific. By comparing these results with epidemiological evidence, we recapitulate 53-60% of known comorbidities distinctly described for men and women, finding sex-specific transcriptomic similarities between sex-specific comorbid diseases. The analysis of shared underlying pathways shows that diseases can co-occur in men and women by altering alternative biological processes. Finally, we identify different drugs differentially associated with comorbid diseases depending on patients sex, highlighting the need to consider this relevant variable in the administration of drugs due to their possible influence on comorbidities.

bioinformatics↗

Exploring the Boundaries of Medulloblastoma Subgroups with Synthetic Data Generation

Medulloblastoma is a childhood brain tumor traditionally classified into four molecular subgroups. Recent evidence suggests that Groups 3 and 4 represent a biological continuum rather than distinct entities, a paradigm shift with significant implications for understanding disease biology and treatment strategies. Nevertheless, assessing this hypothesis is challenging mainly due to data scarcity. In this study, we analyze the largest available transcriptomics dataset to provide compelling evidence for the existence of an intermediate subgroup between Groups 3 and 4, characterized by distinct molecular features. To overcome limitations posed by data scarcity, we employ synthetic data generation using a Variational Autoencoder and apply explainability techniques to identify key relationships between gene expression and disease subgroups. Furthermore, by incorporating Machine Learning Fairness approaches, we demonstrate that overlooking this intermediate subgroup can result in treatment disparities. Our findings are further supported by both existing and newly proposed studies using diverse datasets and methodologies, including graphbased analyses and multi-scale simulations, underscoring the robustness and reproducibility of our results. This study demonstrates the potential of synthetic data generation to refine rare disease subtyping and advance our understanding of the underlying biological mechanisms. Keywords: Medulloblastoma, pediatric cancer, representation learning, autoencoder, synthetic data

bioinformatics↗

Rare disease research workflow using multilayer networks elucidates the molecular determinants of severity in Congenital Myasthenic Syndromes

Exploring the molecular basis of disease severity in rare disease scenarios is a challenging task provided the limitations on data availability. Causative genes have been described for Congenital Myasthenic Syndromes (CMS), a group of diverse minority neuromuscular junction (NMJ) disorders; yet a molecular explanation for the phenotypic severity differences remains unclear. Here, we present a workflow to explore the functional relationships between CMS causal genes and altered genes from each patient, based on multilayer network analysis of protein-protein interactions, pathways and metabolomics. Our results show that CMS severity can be ascribed to the personalized impairment of extracellular matrix components and postsynaptic modulators of acetylcholine receptor (AChR) clustering. We explore this in more detail for one of the proteins not previously associated with the NMJ, USH2A. Loss of the zebrafish USH2A ortholog revealed some effects on early movement and gross NMJ morphology. This work showcases how coupling multilayer network analysis with personalized -omics information provides molecular explanations to the varying severity of rare diseases; paving the way for sorting out similar cases in other rare diseases.

bioinformatics↗

Reconstructing protein interactions at enhancer-promoter regions in prostate cancer

Here we introduce Promoter-ENhancer-GUided Interaction Networks (PENGUIN), a method to uncover protein-protein interaction (PPI) networks at enhancer-promoter contacts. By integrating H3K27ac-HiChIP data and tissue-specific PPI information, PENGUIN enables cluster enhancers-promoter PPI networks (EPINs) and pinpoint actionable factors. Validating PENGUIN in cancer (LNCaP) and benign (LHSAR) prostate cell lines, we observed distinct CTCF-enriched clusters, which identifies diverse chromatin conformations. In LNCaP, we found an EPIN cluster enriched with oncogenes and prostate cancer-associated SNPs. We uncovered a total of 208 SNPs in LNCaP EPINs and used CRISPR/Cas9 knockout and RNAi screens to confirm their relevance. PENGUINs application in prostate cancer demonstrates its potential for studying human diseases. The approach allows exploration in different cell types and combinations of GWAS data, offering promising avenues for future investigations. In conclusion, PENGUIN provides valuable insights into the interplay between enhancer-promoter interactions and PPI networks, facilitating the identification of relevant genes and potential intervention targets.

cancer biology↗

Characterization of genomic variants associated with resistance to bedaquiline and delamanid in naïve Mycobacterium tuberculosis clinical strains

The role of genetic mutations in genes associated to phenotypic resistance to bedaquiline (BDQ) and delamanid (DLM) in Mycobacterium tuberculosis complex (MTBc) strains is poorly understood. However, a clear understanding of the role of each genetic variant is crucial to guide the development of molecular-based drug susceptibility testing (DST). In this work, we analysed all mutations in candidate genomic regions associated with BDQ- and DLM-resistant phenotypes using a whole genome sequencing (WGS) dataset from a collection of 4795 MTBc clinical isolates from six high-burden countries of tuberculosis (TB). From WGS analysis, we identified 61 and 158 unique mutations in genomic regions potentially involved in BDQ- and DLM-resistant phenotypes, respectively. Importantly, all strains were isolated from patients who likely have never been exposed to the medicines. In order to characterize the role of mutations, we performed an energetic in silico analysis to evaluate their effect in the available protein structures Ddn (DLM), Fgd1 (DLM) and Rv0678 (BDQ), and minimum inhibitory concentration (MIC) assays on a subset of MTBc strains carrying mutations to assess their phenotypic effect. The combination of structural protein information and phenotypic data allowed for cataloging the mutations clearly associated with resistance to BDQ (n= 4) and DLM (n= 35), as well as about a hundred genetic variants without any correlation with resistance. Importantly, these results show that both BDQ and DLM resistance-related mutations are diverse and distributed across the entire region of each gene target, which is of critical importance to the development of comprehensive molecular diagnostic tools. ImportancePhenotypic drug susceptibility tests (DST) are too slow to provide an early indication of drug susceptibility status at the time of treatment initiation and very demanding in terms of specimens handling and biosafety. The development of molecular assays to detect resistance to bedaquiline (BDQ) and delamanid (DLM) requires accurate categorization of genetic variants according to their association with phenotypic resistance. We have evaluated a large multi-country set of clinical isolates to identify mutations associated with increased minimum inhibitory concentrations (MICs) and used an in silico protein structure analysis to further unravel the potential role of these mutations in drug resistance mechanisms. The results of this study are an important source of information for the development of molecular diagnostic tests to improve the provision of appropriate treatment and care to TB patients.

microbiology↗

Graph analytics for phenome-genome associations inference

MotivationBiological ontologies, such as the Human Phenotype Ontology (HPO) and the Gene Ontology (GO), are extensively used in biomedical research to find enrichment in the annotations of specific gene sets. However, the interpretation of the encoded information would greatly benefit from methods that effectively interoperate between multiple ontologies providing molecular details of disease-related features.\n\nResultsIn this work, we present a statistical framework based on graph theory to infer direct associations between HPO and GO terms that do not share co-annotated genes. The method enables to map genotypic features to phenotypic features thus providing a valid tool for bridging functional and pathological annotations. We validated the results by (a) supporting evidence of known drug-target associations (PanDrugs), protein-protein physical and functional interactions (BioGRID and STRING), and common pathways (Reactome); (b) comparing relationships inferred from early ontology releases with knowledge contained in the latest versions.\n\nApplicationsWe applied our method to improve the interpretation of molecular processes involved in pathological conditions, illustrating the applicability of our predictions with a number of biological examples. In particular, we applied our method to expand the list of relevant genes from standard functional enrichment analysis of high-throughput experimental results in the context of comorbidities between Alzheimers disease, Lung Cancer and Glioblastoma. Moreover, we analyzed pathways linked to predicted phenotype-genotype associations getting insights into the molecular actors of cellular senescence in Proteus syndrome.\n\nAvailabilityhttps://github.com/dariogarcia/phenotype-genotype_graph_characterization

bioinformatics↗